News - Rare diseases, Hematology

Filter

Current filters:

Rare diseasesHematology

Popular Filters

Baxter buys AesRx, gaining rights to investigational SCD drug

Baxter buys AesRx, gaining rights to investigational SCD drug

10-07-2014

US drugmaker Baxter International said yesterday that it has acquired AesRx, a private US biopharmaceutical…

Aes-103AesRxBaxter InternationalBiotechnologyHematologyMergers & AcquisitionsRare diseasesUSA

Novo Nordisk gains FDA backing for new NovoSeven RT indication

Novo Nordisk gains FDA backing for new NovoSeven RT indication

09-07-2014

Danish diabetes care giant Novo Nordisk’s hemophilia treatment NovoSeven RT (coagulation factor VIIa…

HematologyNovo NordiskNovoSevenNovoSeven RTPharmaceuticalRare diseasesRegulationUSA

US orphan designation for OPKO's longer-acting clotting Factor VIIa-CTP

US orphan designation for OPKO's longer-acting clotting Factor VIIa-CTP

03-03-2014

The US Food and Drug Administration has granted orphan drug designation to US drugmaker OPKO Health’s…

HematologyNorth AmericaOPKO HealthPharmaceuticalRare diseasesUSA

FDA approves Novo Nordisk’s Tretten to treat rare genetic clotting disorder

FDA approves Novo Nordisk’s Tretten to treat rare genetic clotting disorder

24-12-2013

The US Food and Drug Administration yesterday (December 23) approved Tretten, coagulation factor XIII…

HematologyNorth AmericaNovo NordiskNovoThirteenPharmaceuticalRare diseasesRegulationTretten

Citing “unreasonable price,” New Zealand declines eculizumab funding

Citing “unreasonable price,” New Zealand declines eculizumab funding

13-12-2013

New Zealand’s Pharmaceutical Management Agency PHARMAC has declined the funding application for eculizumab…

Alexion PharmaceuticalsAsia-PacificeculizumabGlaxoSmithKlineHematologyNew ZealandPharmaceuticalPricingRare diseasesRevoladeSoliris

Novo Nordisk’s NovoEight passes first stage of Japanese approval

Novo Nordisk’s NovoEight passes first stage of Japanese approval

18-11-2013

Danish insulin giant Novo Nordisk’s recombinant factor VIII product NovoEight (turoctocog alfa) has…

Asia-PacificHematologyNovo NordiskNovoEightPharmaceuticalRare diseasesRegulation

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top